Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis has received positive recommendation for Multaq, from the National Institute for Health and Clinical Excellence (NICE) in England and Wales, for the management of patients with atrial fibrillation (AF).
Subscribe to our email newsletter
Sanofi-aventis said that the NICE appraisal committee’s preliminary recommendation is to endorse Multaq as a first choice therapeutic option after beta-blockers, which are the initial therapeutic option in the NICE clinical guidelines. Based on this recommendation, Multaq should be prescribed in non-permanent AF patients with cardiovascular risk factors.
Belen Garijo, senior vice president of pharmaceutical operations for Europe at sanofi-aventis, said: “Sanofi-aventis is pleased that NICE has acknowledged the benefits of Multaq for non-permanent AF patients who have been awaiting a new therapeutic option that safely treats their symptoms and improves their long-term cardiovascular outcomes.
“We appreciate the thorough and comprehensive evaluation of the Multaq clinical and economic dossier that NICE has performed and believe that this preliminary recommendation by NICE provides a valuable benchmark to guide sanofi-aventis’ ongoing efforts to have the Multaq value proposition in AF patients recognized within Europe and beyond.”
Multaq is expected to be commercially available in the UK from March 30, 2010.